“Great practice with nice staff and professional service. Dr. Paul Lagonigro listens to you and helps you understand what is going on. I'd recommend them to anyone”
Avastin for Eye Conditions: What Patients Should Know
What the Research Shows
Bevacizumab has been studied in some of the largest clinical trials ever conducted in retinal medicine. The evidence consistently supports its effectiveness for several serious retinal conditions.
The Comparison of Age-Related Macular Degeneration Treatments Trials, known as the CATT trial, enrolled more than 1,200 patients across dozens of clinical centers in the United States. It compared bevacizumab to ranibizumab (Lucentis), which at the time was FDA-approved specifically for wet age-related macular degeneration (AMD). Both medications produced equivalent vision improvements in patients with wet AMD, establishing bevacizumab as a clinically effective alternative.
The IVAN trial, conducted in the United Kingdom, independently confirmed the CATT findings. Both bevacizumab and ranibizumab produced similar visual outcomes in wet AMD patients across both study populations. Bevacizumab has also been studied in patients with diabetic macular edema and macular edema caused by retinal vein occlusion, with evidence supporting its usefulness for these conditions as well.
Five-year follow-up data from the CATT trial showed that roughly half of treated patients maintained visual acuity of 20/40 or better. While some patients experienced gradual decline after the first two years, the long-term data confirmed that anti-VEGF treatment, including bevacizumab, provides meaningful visual benefit for patients with wet AMD when used consistently over time.
What to Expect During Your Injection Appointment
The injection process is straightforward and well-tolerated by most patients. Knowing what to expect before, during, and after the procedure can help reduce any anxiety about treatment.
Before the injection, your retina specialist will apply numbing drops to your eye to keep you comfortable. An antiseptic solution is used to clean the surface of the eye and reduce the risk of infection. Some patients also receive a small amount of additional numbing medication around the eye. This preparation takes only a few minutes.
The injection is performed with a very thin needle that delivers the medication through the white part of the eye into the vitreous, which is the clear gel that fills the inside of the eye. The injection takes only a few seconds. Most patients feel a brief sense of pressure rather than sharp pain. The full appointment, from check-in to departure, typically lasts between 30 minutes and one hour.
Mild redness at the injection site, a gritty sensation, or temporary blurred vision are common in the hours following the procedure. These effects generally resolve on their own within a day. Your retina specialist may check your eye pressure before you leave. You can return to most normal activities the same day, though you should avoid rubbing your eye for the remainder of the day.
For a few days after the injection, also avoid swimming, hot tubs, and dusty environments, as these can increase the risk of infection at the injection site.
Treatment Schedules and Ongoing Care
Retinal conditions treated with bevacizumab typically require a long-term commitment to injections and monitoring. Your treatment schedule will be tailored to your specific condition and how your retina responds over time.
Treatment usually begins with monthly injections for the first several months. After that initial phase, your retina specialist will adjust the schedule based on your imaging results and vision changes. Many patients continue receiving injections every four to eight weeks over the long term to keep their condition stable.
A commonly used strategy called treat-and-extend involves gradually increasing the time between injections as long as the retina remains stable on imaging. If fluid returns or the condition worsens, the interval is shortened again. This approach helps maintain visual gains while reducing the total number of office visits over time.
Most retinal conditions treated with anti-VEGF injections require ongoing treatment to remain stable. Stopping injections early or allowing long gaps between visits can allow fluid to return and vision to decline. Even when your vision feels unchanged, continuing your scheduled injections and imaging appointments is essential for protecting the gains you have achieved. If you need to reschedule, contact our office as soon as possible to avoid extended treatment gaps.
Benefits and Risks of Bevacizumab
Bevacizumab has a well-established safety and effectiveness profile based on decades of clinical use in ophthalmology. Understanding both the benefits and the risks helps you make informed decisions alongside your retina specialist.
Multiple large clinical trials have demonstrated that bevacizumab is effective for treating wet AMD, diabetic macular edema, and macular edema related to retinal vein occlusion. For many patients, regular injections successfully stabilize vision or produce meaningful improvement. Large-scale reviews of intravitreal bevacizumab injections have found that serious complications occur in a very small percentage of cases.
The most frequently reported side effects include redness at the injection site, mild discomfort, temporary floaters, and short-term blurred vision. These are consistent with all intravitreal injections and are not unique to bevacizumab. Most side effects resolve on their own within a few days without any treatment.
As with any intravitreal injection, rare but serious risks include eye infection (called endophthalmitis), retinal detachment, elevated eye pressure, and bleeding inside the eye. Because bevacizumab is repackaged at compounding pharmacies rather than manufactured in single-use eye-specific vials, maintaining strict sterility during this process is an important safety consideration. Our team sources bevacizumab from trusted, regulated compounding pharmacies that meet quality standards.
Contact your retina specialist or go to the emergency room immediately if you experience sudden vision loss, severe eye pain, or rapidly worsening redness after an injection. These symptoms require prompt evaluation.
How Avastin Compares to Other Anti-VEGF Medications
Bevacizumab is one of several anti-VEGF medications used to treat retinal disease. Understanding how it fits within the broader range of options can help you have a more informed conversation with your retina specialist.
Several anti-VEGF medications are FDA-approved specifically for retinal use. Lucentis (ranibizumab) is given monthly or on a treat-and-extend schedule. Eylea (aflibercept) and high-dose Eylea offer dosing intervals that may extend to several months in appropriate patients. Vabysmo (faricimab) targets both VEGF and a second protein called angiopoietin-2, and may also allow extended dosing intervals. Clinical trials have shown that bevacizumab produces comparable visual outcomes to these alternatives for wet AMD.
The most important distinction is that Avastin is not FDA-approved for eye conditions. It was developed and approved for cancer treatment, and its use in ophthalmology is off-label, though thoroughly studied. FDA-approved retinal medications are manufactured in single-use vials designed specifically for eye injection, whereas bevacizumab requires repackaging from larger cancer-treatment vials at a compounding pharmacy. Your retina specialist can review your specific condition, imaging results, and treatment history to help determine which medication is the most appropriate choice for you.
Frequently Asked Questions
Below are answers to common questions about bevacizumab for eye conditions, including guidance on making treatment decisions and recognizing when to seek urgent care.
Off-label use means the FDA has not formally approved the drug for that specific indication, but it does not mean the use is experimental or unsafe. The CATT trial and other large studies have demonstrated that bevacizumab has a safety profile comparable to FDA-approved alternatives for retinal conditions. The main safety consideration specific to bevacizumab is the compounding process used to prepare eye-appropriate doses. Our team works with regulated compounding pharmacies that follow strict quality and sterility standards, which significantly reduces this risk.
The choice between bevacizumab and FDA-approved options depends on your specific diagnosis, the severity of your condition, your imaging findings, and factors such as dosing interval preferences. Newer medications like Vabysmo and high-dose Eylea may allow longer intervals between injections, which can reduce the overall treatment burden. Your retina specialist will review all of these factors with you and recommend a treatment plan based on your individual clinical picture rather than a one-size-fits-all approach.
Missing an injection or significantly delaying treatment can allow fluid to return to the retina and vision to decline. The effects of a missed dose vary depending on the condition being treated and how stable your retina has been. If you cannot make a scheduled appointment, contact our office as soon as possible to reschedule at the earliest available time. Do not simply wait until your next regularly scheduled visit if a significant gap has opened up, as earlier evaluation is safer.
Most retinal conditions that respond to anti-VEGF therapy require ongoing treatment to remain stable, often for years. Some patients are able to gradually extend the time between injections as their condition stabilizes, and a small number eventually reach a point where injections can be paused under close monitoring. However, it is important to understand that stopping treatment entirely often leads to recurrence of fluid and vision loss. Your retina specialist will guide this process based on your imaging and vision at each visit.
Mild redness, temporary blurred vision, and a gritty feeling are normal and expected after an injection. However, sudden or severe worsening of vision, intense eye pain, significantly increased floaters, flashes of light, or a shadow or curtain spreading across your vision are not normal and require immediate evaluation. These symptoms may indicate a serious complication such as endophthalmitis or retinal detachment, both of which require urgent treatment. Do not wait for your next scheduled appointment if you experience any of these warning signs.
Yes. While wet AMD is the condition most associated with bevacizumab in clinical research, it is also commonly used off-label for diabetic macular edema, macular edema caused by retinal vein occlusion, and other conditions involving abnormal retinal blood vessels. The appropriateness of bevacizumab for your specific diagnosis depends on factors your retina specialist will evaluate through examination and imaging. If you have been recently diagnosed with any of these conditions, an early consultation is worthwhile since earlier treatment generally leads to better long-term outcomes.
Schedule a Consultation with Our Team
At Atlantic Retina Center, our fellowship-trained, board-certified retina specialists have extensive experience managing wet AMD, diabetic macular edema, retinal vein occlusion, and other conditions treated with bevacizumab and other anti-VEGF therapies. We serve patients across the Eastern Shore of Maryland and central and southern Delaware with offices in multiple locations for your convenience. If you have questions about Avastin or want to explore whether anti-VEGF treatment is right for you, we encourage you to reach out and schedule a consultation with our team.